|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1992-2-6
|
|
pubmed:abstractText |
In a prospective study of 20 patients with NMS, those who received dantrolene (2 patients) or bromocriptine (2 patients) or both (4 patients) tended to have a more prolonged course of illness and a greater incidence of sequelae than those treated with supportive care alone. These results do not indicate a useful role for dantrolene or bromocriptine in the treatment of NMS.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-1250
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
159
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
709-12
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:1843801-Adult,
pubmed-meshheading:1843801-Bromocriptine,
pubmed-meshheading:1843801-Combined Modality Therapy,
pubmed-meshheading:1843801-Critical Care,
pubmed-meshheading:1843801-Dantrolene,
pubmed-meshheading:1843801-Female,
pubmed-meshheading:1843801-Humans,
pubmed-meshheading:1843801-Male,
pubmed-meshheading:1843801-Middle Aged,
pubmed-meshheading:1843801-Neuroleptic Malignant Syndrome,
pubmed-meshheading:1843801-Neurologic Examination,
pubmed-meshheading:1843801-Prospective Studies
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?
|
|
pubmed:affiliation |
Department of Psychiatry, McMaster University Medical Centre, Hamilton, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article
|
